BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Amendments to the Claims:

Please amend the claims by replacing all prior versions of the claims pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as follows:

Listing of Claims:

1-13. (Previously Cancelled)

14. (Previously Amended) The compound of claim 59, wherein the compound comprises the (-) enantiomer.

15. (Previously Amended) The compound of claim 59, wherein the compound comprises the (+) enantiomer.

16. (Previously Amended) The compound of claim 59 having the structure:



17-19. (Previously Cancelled)

20. (Previously Amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 59 and a pharmaceutically acceptable carrier.

21. (Original) The pharmaceutical composition of claim 20 wherein the amount of the compound is an amount from about 0.01 mg to about 500 mg.

22. (Original) The pharmaceutical composition of claim 21 wherein the amount of the compound is from about 0.1 mg to about 60 mg.

23. (Original) The pharmaceutical composition of claim 22 wherein the amount of the compound is from about 1 mg to about 20 mg.

24. (Previously Cancelled)

25. (Original) The pharmaceutical composition of claim 20, wherein the carrier is a solid and the composition is a tablet.

26. (Previously Cancelled)

27. (Original) The pharmaceutical composition of claim 20, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.

28. (Previously Amended) A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 59 effective to treat benign prostatic hyperplasia.

29. (Previously Amended) The method of claim 28, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.

30. (Original) The method of claim 29, wherein the compound effects treatment of benign prostatic hyperplasia by relaxing lower urinary tract tissue.

31. (Original) The method of claim 30, wherein lower urinary tract tissue is prostatic smooth muscle.

32-40. (Previously Cancelled)

41. (Previously Amended) A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 59 in combination with a 5 alpha-reductase inhibitor effective to treat benign prostatic hyperplasia.

42. (Original) The method of claim 41, wherein the 5-alpha reductase inhibitor is finasteride.

43-44. (Previously Cancelled)

45. (Previously Amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 59 in combination with a therapeutically effective amount of

finasteride and a pharmaceutically acceptable carrier.

46-58. (Previously Cancelled)

59. (Currently Amended) A compound having the structure:



wherein A is



wherein each of Y_1, Y_2, Y_3, Y_4 and Y_5 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-OCOR_4$, $-COR_4$, $-CONHR_4$, $-CON(R_4)_2$, or $-COOR_4$; or any two of Y_1, Y_2, Y_3, Y_4 and Y_5

present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein X is S; O; or NR_4;

wherein B is -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; alkoxy or thioalkyl; straight chained or branched C_2-C_7 alkenyl; ~~$-SCH_2C_6H_4OR_4$~~, $-(CH_2)_nC_6H_5$, $-CH_2X(CH_2)_nNHR_4$; $-(CH_2)_nNHR_4$ or $-OR_4$ with the proviso that B cannot be -OH or $-OCH_3$;

wherein R_1 is -H; $-NO_2$; -CN; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; $-N(R_4)_2$; $-OR_4$; $-(CH_2)_pOR_4$; $-COR_4$; $-CO_2R_4$; or ~~$-CON(R_4)2$~~ $-CON(R_4)_2$;

wherein R_2 is -H; straight chained or branched C_1-C_7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C_3-C_{10} cycloalkyl-C_1-C_{10}-alkyl, C_3-C_{10} cycloalkyl-C_1-C_{10}-monofluoroalkyl or C_3-C_{10} cycloalkyl-C_1-C_{10}-polyfluoroalkyl; -CN; $-CH_2XR_4$, $-CH_2X(CH_2)_pNHR_4$, $-(CH_2)_nNHR_4$, $-CH_2X(CH_2)_pN(R_4)_2$, or $-CH_2X(CH_2)_pNHCXR_7$; or $-OR_4$;

wherein each p is independently an integer from 1 to 7;

wherein each n is independently an integer from 0 to 5;

wherein R_3 is



;

wherein Z is C_2-C_7 alkenyl or alkynyl; CH_2; O; CO; CO_2 $CONR_4$; S; SO; SO_2; or NR_4;

wherein each V is independently O; S; CH_2; CR_5R_7; $C(R_7)_2$; or NR_7;

wherein each m is independently an integer from 0 to 3;

wherein each R is independently -H; -F; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; -$N(R_4)_2$; -NO_2; -CN; -CO_2R_4; or -OR_4;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

wherein R_5 is aryl or heteroaryl substituted with one or more ~~F~~ -F; ~~Cl~~ -Cl; ~~Br~~ -Br; ~~I~~ -I; ~~COR_3~~; ~~CO_2R_3~~ -CO_2CH_3; ~~$CON(R_3)_2$~~ -$CONH_2$; ~~CN~~ -CN; -NO_2; ~~$N(R_3)_2$~~ -NH_2; ~~OR_3~~ -OCH_3; ~~SR_3~~; -SCH_3; ~~$(CH_2)_eOR_3$~~; ~~$(CH_2)_eSR_3$~~; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C_2-C_7

alkenyl; C_2-C_7 alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl, or cycloalkenyl;

wherein each R_6 is independently -H; straight chained or branched C_1-C_7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; or $-OR_4$;

wherein R_7 is aryl or heteroaryl substituted with one or more ~~F~~ -F; ~~Cl~~ -Cl; ~~Br~~ -Br; ~~I~~ -I; ~~COR_4~~; ~~CO_2R_4~~ $-CO_2CH_3$; ~~$-CON(R_4)_2$~~ $-CONH_2$; ~~CN~~ -CN; $-NO_2$; ~~$-N(R_4)_2$~~ $-NH_2$; ~~$-OR_4$~~ $-OCH_3$; ~~$-SR_4$~~; $-SCH_3$; ~~$(CH_2)_eOR_4$~~; ~~$(CH_2)_eSR_4$~~; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C_2-C_7 alkenyl; C_2-C_7 alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl, or cycloalkenyl;

or a pharmaceutically acceptable salt thereof.

60. (Previously Presented) The compound of claim 59 having the structure:



61. (Previously Presented) A compound selected from the group consisting of:


and


62-65. (Currently Cancelled)

66. (Currently amended) A compound having the structure:




67. (Currently Amended) A compound having the structure: